Evotec hits milestone in neurodegeneration deal with Bristol

Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) 
announced today that the Company has received a US$ 6 m payment from Bristol 
Myers Squibb Company (NYSE:BMY) within the companies' iPSC-based 
neuroscience partnership. The payment follows Bristol Myers Squibb's 
decision to add another drug discovery project to the partnership's 
portfolio. 
 
Evotec and Bristol Myers Squibb (the successor in interest to Celgene) 
initiated the collaboration in 2016 to identify disease-modifying treatments 
for a broad range of neurodegenerative diseases. Currently approved drugs 
only offer short-term management of patients' symptoms and there is a huge 
unmet medical need for therapies that slow down or reverse disease 
progression in the field of neurodegenerative diseases. 
 
This collaboration pursues an innovative approach to the discovery and 
development of novel medicines by leveraging several of Evotec's unique 
technology platforms in conjunction with the human iPSC-based platform, 
which is one of the largest and most sophisticated platforms in the 
industry. The partnership between Bristol Myers Squibb and Evotec has 
already found several access points into neurodegenerative diseases and has 
to-date delivered a broad portfolio targeting key disease mechanisms in  

neurodegeneration.

https://www.marketscreener.com/quote/stock/EVOTEC-SE-436047/news/PRESS-RELEASE-EVOTEC-ACHIEVES-MILESTONE-IN-ITS-NEURODEGENERATION-COLLABORATION-WITH-BRISTOL-MYERS-S-32120739/